Polymorphisms in genes related to oxidative stress are associated with inferior cognitive function after therapy for childhood acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2205-2211

  Cole, Peter D ^a   Finkelstein, Yaron ^b   Stevenson, Kristen E ^d   Blonquist, Traci M ^d   Vijayanathan, Veena ^a   Silverman, Lewis B ^e   Neuberg, Donna S ^d   Sallan, Stephen E ^e   Robaey, Philippe ^c   Waber, Deborah P ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; HFE PROTEIN; METHOTREXATE; PREDNISONE; PROSTAGLANDIN TRANSPORTER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; ASSAY; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD LEUKEMIA; COGNITION; CONTROLLED STUDY; CUSTOMIZED MULTIPLEXED SEQUENOM MASSARRAY ASSAY; DISEASE ASSESSMENT; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; INTELLIGENCE QUOTIENT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION BASED ALLELIC DISCRIMINATION ASSAY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; COGNITION DISORDERS; GENETICS; INFANT; NEUROPSYCHOLOGICAL TEST; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PSYCHOLOGY; SURVIVOR;

ADOLESCENT; ALLELES; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS;

EID: 84936969259     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0273     Document Type: Article

References (49)

1. Hudson MM, Link MP, Simone JV: Milestones in the curability of pediatric cancers. J Clin Oncol 32:2391-2397, 2014
2. Duffner PK, Armstrong FD, Chen L, et al: Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) Acute Lymphoblastic Leukemia Protocols (ACCL0131): A methotrexate consequence? A Report From the Children's Oncology Group. J Pediatr Hematol Oncol 36:8-15, 2014
3. Hodgson KD, Hutchinson AD, Wilson CJ, et al: A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39:297-304, 2013
4. Krull KR, Brinkman TM, Li C, et al: Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. J Clin Oncol 31:4407-4415, 2013
5. Conklin HM, Krull KR, Reddick WE, et al: Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 104:1386-1395, 2012
6. Moyer KH, Willard VW, Gross AM, et al: The impact of attention on social functioning in survivors of pediatric acute lymphoblastic leukemia and brain tumors. Pediatr Blood Cancer 59:1290-1295, 2012
7. Krull KR, Jain N, Pan Z, et al: Executive functions in aging adult survivors of childhood leukemia. J Clin Oncol 28:638s, 2010 (abstr 9011)
8. Ashford J, Schoffstall C, Reddick WE, et al: Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer 116:4638-4645, 2010
9. Buizer AI, de Sonneville LM, Veerman AJ, et al: Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: A critical review of the literature. Pediatr Blood Cancer 52:447-454, 2009
10. Lofstad GE, Reinfjell T, Hestad K, et al: Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr 98:180-186, 2009
11. Peterson CC, Johnson CE, Ramirez LY, et al: A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 51:99-104, 2008
12. Mrakotsky CM, Silverman LB, Dahlberg SE, et al: Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer 57:492-498, 2011
13. Monje M, Thomason ME, Rigolo L, et al: Functional and structural differences in the hippocampus associated with memory deficits in adult survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer 60:293-300, 2013
14. Zeller B, Tamnes CK, Kanellopoulos A, et al: Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2078-2085, 2013
15. Lo Nigro L, Di Cataldo A, Schiliro G: Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 35:449-455, 2000
16. Brouwers P: Commentary: Study of the neurobehavioral consequences of childhood cancer: Entering the genomic era? J Pediatr Psychol 30:79-84, 2005
17. Krajinovic M, Robaey P, Chiasson S, et al: Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 6:293-302, 2005
18. Krull KR, Bhojwani D, Conklin HM, et al: Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2182-2188, 2013
19. Vezmar S, Becker A, Bode U, et al: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92-104, 2003
20. Froklage FEAM, Reijneveld JC, Heimans JJ: Central neurotoxicity in cancer chemotherapy: Pharmacogenetic insights. Pharmacogenomics 12:379-395, 2011
21. Quinn CT, Kamen BA: A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 44:522-530, 1996
22. Cole PD, Kamen BA: Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev 12:174-183, 2006
23. Bhojwani D, Sabin ND, Pei D, et al: Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32:949-959, 2014
24. Kishi S, Griener J, Cheng C, et al: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21:3084-3091, 2003
25. Cole PD, Beckwith KA, Vijayanathan V, et al: Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr Neurol 40:34-41, 2009
26. Bellamy MF, McDowell IF: Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 20:307-315, 1997
27. Ho PI, Ashline D, Dhitavat S, et al: Folate deprivation induces neurodegeneration: Roles of oxidative stress and increased homocysteine. Neurobiol Dis 14:32-42, 2003
28. Lipton SA, Kim WK, Choi YB, et al: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94:5923-5928, 1997
29. Vijayanathan V, Ali N, Gulinello M, et al: Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav Brain Res 225:491-497, 2011
30. Packan DR, Sapolsky RM: Glucocorticoid endangerment of the hippocampus: Tissue, steroid and receptor specificity. Neuroendocrinology 51:613-618, 1990
31. Hockenberry MJ, Taylor OA, Gundy PM, et al: F2-isoprostanes: A measure of oxidative stress in children receiving treatment for leukemia. Biol Res Nurs 16:303-309, 2013
32. Meyers CA, Albitar M, Estey E: Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104:788-793, 2005
33. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896-904, 2007
34. Vrooman LM, Stevenson KE, Supko JG, et al: Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 31:1202-1210, 2013
35. Waber DP, McCabe M, Sebree M, et al: Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01. Pediatr Blood Cancer 60:1785-1791, 2013
36. Waber DP, Queally JT, Catania L, et al: Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL Consortium Protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer 58:758-765, 2012
37. Axelrod BN: Validity of the Wechsler abbreviated scale of intelligence and other very short forms of estimating intellectual functioning. Assessment 9:17-23, 2002
38. Wechsler D: Wechsler Intelligence Scale for Children (ed 3). San Antonio, TX, Psychological Corporation, 1991
39. Bernstein JH: Developmental Scoring System for the Rey-Osterrieth Complex Figure. Odessa, FL, Psychological Assessment Resources, 1996
40. Reynolds C, Kamphaus R: BASC: Behavioral Assessment System for Children. Circle Pines, MN, American Guidance Service, 2004
41. Houtenville A, Ruiz T: 2011 Annual Disability Statistics Compendium. Durham, NH, University of New Hampshire, Institute on Disability, 2011
42. Kamdar KY, Krull KR, El-Zein RA, et al: Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. Pediatric Blood & Cancer 57:454-460, 2011
43. Li Y, Vijayanathan V, Gulinello M, et al: Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav 95:428-433, 2010
44. Nandar W, Neely EB, Unger E, et al: A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. Biochim Biochim Biophys Acta 1832:729-741, 2013
45. Strange RC, Spiteri MA, Ramachandran S, et al: Glutathione-S-transferase family of enzymes. Mutat Res 482:21-26, 2001
46. Li Y, Vijayanathan V, Gulinello ME, et al: Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. Pharmacol Biochem Behav 94:454-463, 2010
47. Lotta T, Vidgren J, Tilgmann C, et al: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210, 1995
48. Miller JW, Selhub J, Joseph JA: Oxidative damage caused by free radicals produced during catecholamine autoxidation: Protective effects of O-methylation and melatonin. Free Radic Biol Med 21:241-249, 1996
49. Nappi AJ, Vass E: Hydroxyl radical formation via iron-mediated Fenton chemistry is inhibited by methylated catechols. Biochimica et Biophysica Acta 1425:159-167, 1998